10 Recent Oncology Drug Approvals

Slideshow

This slideshow summarizes recent US Food and Drug Administration approvals of new oncology drugs and oncology drug indications.

With rapid advancements in the field of oncology come frequent US Food and Drug Administration (FDA) approvals of new oncology drugs, as well as updates to the indications and warnings of existing therapies. In 2018, 17 of 59 new drug approvals (29%) were oncology-related, and the trend seems to continue so far in 2019. This slideshow highlights several newly approved oncology drugs or those with new indications in 2018 and the first quarter of 2019.

Related Videos
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.